0,funded trial The was published is manufacturer the Journal the T-VEC Oncology Clinical 
2,submitted drug The has available could in Europe been FDA both Agency the developed Amgen company be patients US year next approved if soon afterwards the European Medicines 
3,reported Findings trial the are Journal the funded Amgen biopharmaceutical Oncology Clinical company manufactures which T-Vec 
4,selected Researchers randomly patients 436 melanoma advanced inoperable receive to injection an T-VEC made Amgen company 
